Search company, investor...

InflaRx

inflarx.com

Stage

IPO | IPO

Total Raised

$89M

Date of IPO

11/8/2017

Market Cap

0.11B

Stock Price

2.50

About InflaRx

InflaRx is a biopharmaceutical company developing new therapeutics in the terminal complement space. InflaRx focuses on applying its proprietary anti-C5a technology to discover and develop specific inhibitors of C5a, an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. The company is also developing additional molecules targeting chronic and inflammation-related diseases.

Headquarters Location

Winzerlaer Str. 2

Jena, D-07745,

Germany

+49 (0)3641 508 180

Missing: InflaRx's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: InflaRx's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing InflaRx

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

InflaRx is included in 2 Expert Collections, including Biopharma Tech.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

O

Omics

1,267 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

InflaRx Patents

InflaRx has filed 1 patent.

The 3 most popular patent topics include:

  • Immune system
  • G protein coupled receptors
  • Immunology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

8/7/2019

10/11/2022

Complement system, Inflammations, Immune system, Immunology, G protein coupled receptors

Grant

Application Date

8/7/2019

Grant Date

10/11/2022

Title

Related Topics

Complement system, Inflammations, Immune system, Immunology, G protein coupled receptors

Status

Grant

Latest InflaRx News

InflaRx Reports Third Quarter 2022 Financial & Operating Results

Nov 9, 2022

Jena, GERMANY Vilobelimab earns Orphan Drug and Fast Track designation for the treatment of critically ill, intubated, mechanically ventilated COVID-19 patients - Emergency Use Authorization (EUA) submitted to U.S. Food and Drug Administration (FDA) PANAMO Phase III study results in severe COVID-19 published in peer-reviewed journal, The Lancet Respiratory Medicine Fast Track designation granted for the treatment of pyoderma gangrenosum by FDA Cash, cash equivalents and marketable securities of €93.2 million, expected to finance operations at least until year-end 2024 JENA, Germany, Nov. 09, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today financial and operating results for the three and nine months ended September 30, 2022. “In the past three months, we have made important progress with our lead product candidate, vilobelimab, and are excited about the promise this antibody holds in providing hope to patients with life-threatening acute illness as well as those with chronic, debilitating diseases,” said Prof. Niels C. Riedemann, Chief Executive Officer and Founder of InflaRx. “In late September, following encouraging interactions with the U.S. FDA, we applied for Emergency Use Authorization for the treatment of critically ill, invasively mechanically ventilated COVID-19 patients. We were also pleased that the results from our PANAMO Phase III study in these COVID-19 patients were published in one of the top peer-reviewed journals in the field, concluding on the robust survival benefit these data demonstrated.” Dr. Riedemann continued: “Beyond this, we made important advances we made during the quarter in other development programs. We were granted Fast Track designation for vilobelimab for the treatment of ulcerative pyoderma gangrenosum, a serious neutrophilic skin disease with high unmet medical need, and preparations are underway for a Phase III clinical program. In addition, we expect to initiate clinical trials with a second program, INF904, an orally available C5a receptor inhibitor, before the end of this year. We are excited about the progress in the different development areas and will continue to move our programs forward in the months ahead.” Recent Corporate and R&D Highlights Development of Vilobelimab in Pyoderma Gangrenosum (PG): InflaRx recently reported that vilobelimab was granted Fast Track designation for the treatment of ulcerative PG by the FDA. Previously vilobelimab had been granted Orphan Drug designation by both the FDA in the US and the European Medicines Agency (EMA) for the treatment of ulcerative PG. Following a productive End-of-Phase II meeting with the FDA in Q3 2022, InflaRx is moving forward with plans for a Phase III clinical development program in this indication. Development of Vilobelimab in Severe COVID-19: InflaRx recently announced that it submitted a request for EUA following encouraging interactions with the FDA at a previously held Type B meeting. InflaRx also received Fast Track designation from the FDA for the development of vilobelimab for the treatment of critically ill, intubated, mechanically ventilated COVID-19 patients. The EUA submission and Fast Track designation are based on the topline results from the PANAMO Phase III study, an international, double-blind, placebo-controlled, randomized clinical trial investigating vilobelimab in invasively mechanically ventilated COVID-19 patients. The results from the PANAMO trial were recently published in the peer-reviewed journal, The Lancet Respiratory Medicine, which included an in-depth statistical analysis supporting the robustness of the observed clinical survival benefit in the study. Development of Vilobelimab in Cutaneous Squamous Cell Carcinoma (cSCC): InflaRx has ongoing an open-label, multicenter Phase II study evaluating vilobelimab alone and in combination with pembrolizumab in patients with programmed cell death protein 1 (PD-1) or programmed cell death ligand 1 (PD-L1) inhibitor resistant/refractory, locally advanced or metastatic cSCC. To date, InflaRx has recruited nine patients in Arm A of this study (vilobelimab alone). The interim analysis in Arm A required to proceed to the second stage is expected to be available after ten patients are evaluable for response assessment. Interim clinical data from Arm A are expected in the first half of 2023. Arm B of this study (vilobelimab plus pembrolizumab) has enrolled twelve patients so far in three dose groups. The interim analysis of Arm B is expected once ten patients treated at the same dose level recommended by the independent Steering Committee to move forward with the trial are evaluable for response assessment. These data, which are required to move to the second stage of the Phase II trial, are expected to be available in the second half of 2023. INF904 – Small Molecule C5aR Inhibitor: InflaRx is on track to initiate a Phase I program in the second half of 2022 and plans to study INF904 in complement-mediated, chronic autoimmune and inflammatory diseases where oral administration is the preferred choice for patients. Financial Highlights – Q3 2022  Dr. Thomas Taapken, Chief Financial Officer of InflaRx, said: “Our cash position improved compared to the end of the third quarter, mainly due to cash inflows from a grant from the German government and especially through the strengthening of the US Dollar against the EURO. With a cash runway at least until year-end 2024, we are well financed to build on the significant advances we have made with our clinical programs and to follow through with the next steps, pending feedback from regulatory authorities, in developing vilobelimab both for severe COVID-19 and pyoderma gangrenosum as well as in moving our earlier-stage programs forward.” Research and Development Expenses  Research and development expenses incurred for the nine months ended September 30, 2022 increased compared to the corresponding period in 2021 by €3.6 million to €29.2 million. This increase was primarily due to higher expenses for the Phase III part of the COVID-19 trial as well as costs for manufacturing development activities and was driven by an overall increase in third-party expenses of €1.9 million. General and Administrative Expenses  General and administrative expenses increased by €2.7 million to €11.8 million for the nine months ended September 30, 2022, from €9.1 million for the nine months ended September 30, 2021. This increase is primarily attributable to higher expenses associated with equity-settled share-based compensation recognized in personnel expenses. Furthermore, legal, consulting and other expenses increased by €2.0 million to €5.9 million for the six months ended June 30, 2022, from €3.9 million, mainly due to consulting, implementation and testing costs of the internal control over financial reporting (ICFR) environment. Other income Other income for the nine months ended September 30, 2022 was €16.5 million, which is primarily attributable to income recognized from grant payments received from the German federal government for the development of vilobelimab in severe COVID-19 patients, including expenses related to clinical development and manufacturing process development, Net Financial Result  Net financial result increased by €1.4 million to €3.1 million for the nine months ended September 30, 2022, from €1.7 million for the nine months ended September 30, 2021. This increase is mainly attributable to the strengthening of the USD to EUR during 2022. Net Loss  Net loss for the nine months ended September 30, 2022 was €21.5 million, compared to €33.0 million for the nine months ended September 30, 2021. Net Cash Used in Operating Activities  Net cash used in operating activities increased by €0.3 million to €28.5 million for the nine months ended September 30, 2022 compared to the nine months ended September 30, 2021, during which net cash used in operating activities was €28.2 million. Cash, Cash Equivalents and Marketable Securities On September 30, 2022, the Company’s total funds available were approximately €93.2 million, composed of cash and cash equivalents of €18.0 million and marketable securities of €75.2 million. These funds are expected to finance operations at least until year-end 2024. Additional information regarding these results and other relevant information is included in the notes to the unaudited interim condensed consolidated financial statements as of September 30, 2022, and the three and nine months ended September 30, 2022 and 2021, as well as the consolidated financial statements as of and for the year ended December 31, 2021 in “ITEM 18. Financial Statements,” in InflaRx’s Annual Report on Form 20-F for the year ended December 31, 2021, as filed with the U.S. Securities and Exchange Commission (SEC). InflaRx N.V. and subsidiaries Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and nine months ended September 30, 2022 and 2021

Sep 30, 2022
Why gold? Why now?

InflaRx Frequently Asked Questions (FAQ)

  • Where is InflaRx's headquarters?

    InflaRx's headquarters is located at Winzerlaer Str. 2, Jena.

  • What is InflaRx's latest funding round?

    InflaRx's latest funding round is IPO.

  • How much did InflaRx raise?

    InflaRx raised a total of $89M.

  • Who are the investors of InflaRx?

    Investors of InflaRx include Bain Capital, RA Capital Management, Cormorant Asset Management, Staidson Hongkong Investment, Affentranger Associates and 3 more.

  • Who are InflaRx's competitors?

    Competitors of InflaRx include Constellation Pharmaceuticals, Ambrx, OcuNexus Therapeutics, Momenta Pharmaceuticals, Intarcia Therapeutics and 13 more.

Compare InflaRx to Competitors

I
InteKrin Therapeutics

InteKrin Therapeutics, Inc. is a privately-held clinical stage biopharmaceutical company based in Los Altos, California developing therapeutics for diabetes, obesity and metabolic disorders. The company was founded in 2005 by Denny Lanfear, a former Vice President and Officer of Amgen, and clinical endocrinologist Christos Mantzoros, M.D., DSc, FACP, FACE, Associate Professor of Medicine at Harvard Medical School. InteKrin's Scientific Advisory Board includes veterans from several successful biopharma organizations, internationally recognized experts in nuclear receptors and metabolism as well as top scientists formerly with the Food and Drug Administration. Its lead product, INT131, is a novel SPPARM (Selective Peroxisome Proliferator-Activated Receptor Modulator) which is in Phase II clinical trials for diabetes. The company focuses on high value therapeutics in addressing unmet medical needs. To learn more about InteKrin, visit www.intekrin.com

A
ALEXIS Biochemicals

ALEXIS Biochemicals is an internationally recognized brand acknowldeged as engaged in producing and commercializing high quality reagents in key research areas and an established source for a panel of products to scientific experts in the field.

G
GRAPP

Grand River Aseptic Pharmaceutical Packaging is a pharmaceutical contract manufacturing organization (CMO) supporting the rapid development of new biomedicines to the clinical stage in the State of Michigan. Grand River APP is the result of an alliance between Van Andel Institute (www.vai.org) and Grand Valley State University, and is operating as a non-profit, state- and federally funded corporation. Grand River APP's first aims to assure that therapeutics are properly distributed into dosage forms for all-important Phase I and Phase II human clinical trials. This process, Fill/Finish and Lyophilization, will be offered broadly to academic, nonprofit, and for-profit organizations in Michigan and across North America for liquid-based drug candidates that require vialing in an FDA-regulated aseptic clean room environment. Typical products envisioned for Grand River APP services include small molecule drugs, peptides, monoclonal antibodies, therapeutic proteins and nano-medicines. As a consequence, however, Grand River APP cannot process cytotoxic/genotoxic or virally-based candidates (e.g. viral vaccines).

R
Radio Therapeutics Corporation

Radio Therapeutics Corporation develops and manufactures radiofrequency-based therapeutic devices for the destruction of various forms of soft tissue tumors. RTC markets the Radiofrequency Ablation System, which uses radiofrequency energy to selectively destroy undesirable soft tissue. The technology is based on hyperthermia (overheating) of the tumor to destroy it with the use of a specially designed probe which is inserted into the tumor. The probe architecture is the core of the technology and permits a localized application of radio-frequency energy. The system is used by radiologists and surgical oncologists for the ablation of nonresectable (inoperable) liver lesions.

C
CMP

CMP Therapeutics has developed a treatment for regulating and stimulating the immune system. The lead product is in Phase II clinical trials for allergic disorders. Other pipeline products have shown through stimulation of the immune system to protect against viruses and bacteria.

N
NanoFluence Health

Plans to develop and market food and beverage applications complemented with high-efficacy and high-quality nutraceutical supplements and pharmaceutical systems. Products will feature and incorporate high-concentration EPA & DHA omega-3 oils and calcium complexation ingredients to treat specific health conditions. The highest priority target conditions are disease states resulting from deficiencies in EPA & DHA essential fatty acids and calcium such as ADHD, high-cholesterol, and osteoporosis. NanoFluence has demonstrated a range of food and beverage products featuring omega-3 oils and is conducting formulation and optimization work to reduce both the effective dosage level and the time to realize noticeable gains in treating target conditions.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.